🧠 Food for thought

Implications, context, and why it matters.

 The “AI-designed drug by 2026” claim needs clearer regulatory context

• The idea that China could approve a fully AI-designed drug by 2026 is being treated as plausible, yet the underlying assumption needs support.
• It should be checked whether any fully AI-designed molecules are already in late-stage clinical trials, since drugs typically must move through clinical development before approval by China’s National Medical Products Administration (NMPA) 1.
• It also needs to be verified whether the NMPA has issued detailed guidance on how drugs “designed with AI” are reviewed, as separate from AI software regulated as a medical device 2.

Cross-border data compliance constrains AI drug discovery partnerships

• Merck’s search for Chinese partners and XtalPi’s deals with Pfizer hinge on access to China’s large patient data sets plus clinical-trial and genomic data.
• Tech providers can sell products that help pharmaceutical R&D groups and compliance staff follow China’s cross-border data transfer rules, including for sensitive clinical and genomic information.
• Any platform used for joint work needs a compliant way to share data under the Personal Information Protection Law (PIPL) and the human genetic resources (HGR) regulatory regime. The HGR regime bars foreign entities from collecting or preserving China’s HGR within China, and it restricts sending China’s HGR overseas except under set conditions, often through approved or record-filed collaboration with Chinese partners 3.